Skip to content

Study · Animal study (in vivo) · mouse · 2007

2 results

Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.

Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, Gozes I

The Journal of pharmacology and experimental therapeutics24 Aug 2007Cited by 182 (Europe PMC)

PMID17720885 (opens in a new tab)DOI10.1124/jpet.107.129551 (opens in a new tab)PepBankPUB-17720885
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In ADNP-deficient mice, NAP partially ameliorated cognitive deficits.

    In plain wordsIn mice with partial ADNP deficiency, NAP partly reduced cognitive deficits.

    Peptide
    Davunetide
    Outcome
    DecreaseCognitive deficits
    Study

    mousen: not reported in source

    ADNP(+/-) mice
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NAP treatment partially ameliorated cognitive deficits and reduced tau hyperphosphorylation in the ADNP(+/-) mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In ADNP-deficient mice, NAP reduced tau hyperphosphorylation.

    In plain wordsIn mice with partial ADNP deficiency, NAP reduced excessive tau phosphorylation.

    Peptide
    Davunetide
    Outcome
    DecreaseTau hyperphosphorylation
    Study

    mousen: not reported in source

    ADNP(+/-) mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NAP treatment partially ameliorated cognitive deficits and reduced tau hyperphosphorylation in the ADNP(+/-) mice.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT01056965

Davunetide (AL-108) in Predicted Tauopathies - Pilot Study

University of California, San Franciscon = 12Jan 2010 to Dec 2012

Predicted Tauopathies, Including · Progressive Supranuclear Palsy · Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17 · Corticobasal Degeneration Syndrome · Progressive Nonfluent Aphasia

Trial pageClinicalTrials.govUpdated 5 Apr 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.